Research Analysts Set Expectations for AGIO FY2026 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Agios Pharmaceuticals in a report released on Monday, June 9th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings of ($8.44) per share for the year, down from their prior forecast of ($8.35). HC Wainwright currently has a "Buy" rating and a $58.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals' FY2027 earnings at ($9.38) EPS, FY2028 earnings at ($8.48) EPS and FY2029 earnings at ($6.32) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The firm had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million.

Several other brokerages also recently weighed in on AGIO. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Scotiabank cut their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $56.50.

Agios Pharmaceuticals Price Performance

AGIO stock traded up $0.09 during trading on Thursday, reaching $34.50. 475,511 shares of the stock traded hands, compared to its average volume of 663,762. The business's 50 day moving average price is $29.39 and its 200-day moving average price is $34.08. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The firm has a market capitalization of $2.00 billion, a PE ratio of 3.04 and a beta of 0.73.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Jefferies Financial Group Inc. purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $49,290,000. SCS Capital Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $17,905,000. Adage Capital Partners GP L.L.C. grew its position in shares of Agios Pharmaceuticals by 145.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company's stock valued at $21,770,000 after purchasing an additional 440,000 shares during the last quarter. Palo Alto Investors LP acquired a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $8,104,000. Finally, Paradigm Biocapital Advisors LP acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth about $9,084,000.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. This trade represents a 4.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.93% of the stock is currently owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.